Safety Study of P28GST Treatment in Crohn's Disease Patients (ACROHNEM)
Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Amiens, France
- Centre Hospitalier
-
Boulogne-sur-Mer, France
- Centre Hospitalier de Boulogne
-
Dunkirk, France
- Centre Hospitalier Dunkerque
-
Lille, France, 59037
- CHRU, Hôpital Claude Huriez
-
Valenciennes, France
- Centre Hospitalier,
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects between the ages of ≥18 years at inclusion.
- Subjects with ileal or ileo-colic CD without fistula
- Subjects operated or not
- CDAI score < 220
- no concomitant treatment excepted salicylates
- Women of child bearing potential must be negative for pregnancy prior to study enrolment
- contraceptive means : females of childbearing potential as well as males are required to use adequate contraceptive methods for 6 months starting at the inclusion, i;e 4 months after the 3rd injection .
- No tobacco consumption (end date of tobacco consumption 8 days before surgery).
- Signed consent form
- French social security coverage.
Exclusion Criteria:
- Subject who use of azathioprine, anti-TNF (Tumor Necrosis Factor), methotrexate, Vedolizumab, Ustekinumab and other immunosuppressors for 8 weeks before first injection of P28GST
- Subject who use of corticosteroids for 15 days before first injection of P28GST
- Subject with history of vaccine hyper sensitivity or allergy.
- Subject with any other clinical manifestation determined by the investigator
- Subject wih AIDS, B or C hepatitis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: P28GST treatment
P28GST as a parasite enzyme
|
3 injections of 100 µg of P28GST within 3 months (one injection per month)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants wtih adverse events as a measure of safety and tolerability
Time Frame: up to one year
|
Clinical and blood markers change from baseline
|
up to one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Main immunologic and inflammatory blood and tissue markers.
Time Frame: up to one year
|
up to one year
|
|
|
Appearance or not of a clinical recurrence assessed by CDAI (Crohn Disease Activity Index) and confirmed by a morphologic examination.
Time Frame: up to one year
|
up to one year
|
|
|
Intestinal microbiota
Time Frame: at inclusion, at 4 month , at 12 month
|
Evolution of bacterial species by genomic analysis
|
at inclusion, at 4 month , at 12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Dominique DEPLANQUE, MD, PhD, Lille University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2013_02
- 2013-000595-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.